Truist keeps a Hold rating on Sage Therapeutics (SAGE) after Zurzurvae’s commercial partner Biogen (BIIB) disclosed an unsolicited proposal to acquire the company for $7.22 per share.
We may earn commission from links on this page, but we only recommend products we love. Promise. Over the past month and half, I put the entirety of Hero Cosmetics' line to the test (no, fr, ...